Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA

被引:31
作者
Cai, Liying [2 ]
Zhang, Guangmei [2 ]
Tong, Xiaojing [2 ]
You, Qi [2 ]
An, Yuan [2 ]
Wang, Yuguang [2 ]
Guo, Lei [1 ]
Wang, Tianzhen [3 ]
Zhu, Daling [1 ]
Zheng, Jianhua [2 ]
机构
[1] Harbin Med Univ, Coll Pharm, Dept Biopharmaceut Sci, Harbin, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150001, Heilongjiang, Peoples R China
[3] Harbin Med Univ, Dept Pathol, Harbin, Heilongjiang, Peoples R China
关键词
Human; Ovarian cancer; STAT3; RNA interference; SIGNAL TRANSDUCERS; TRANSCRIPTION-3; EXPRESSION; AUTOCRINE; PATHWAY; KINASE;
D O I
10.1016/j.ejogrb.2009.09.018
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Signal transducer and activator of transcription 3 (STAT3) are constitutively activated in a variety of cancers and it is a common feature of ovarian cancer. Thus, STAT3 represents a promising molecular target for tumor therapy. We applied a DNA vector-based STAT3-specific RNA interference approach which specifically blocks over-activated STAT3, to treat human ovarian cancer cells, and evaluated the cellular proliferation ability and investigated the molecular mechanisms in vitro. Study design: A DNA vector-based RNA interference approach was used to knockdown STAT3 expression in human ovarian cancer cells in vitro. Results: The STAT3 siRNA down-regulated the expression of cyclin D1, survivin, and VEGF in ovarian cancer cells both at transcription and translation levels. Inhibition of STAT3 and its related genes was accompanied by growth suppression and induction of apoptosis in cancer cells in vitro. Conclusions: These data indicate that STAT3 signaling is a promising molecular target for ovarian cancer therapy. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 29 条
  • [1] Alas S, 2001, CANCER RES, V61, P5137
  • [2] Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
    Aoki, Y
    Feldman, GM
    Tosato, G
    [J]. BLOOD, 2003, 101 (04) : 1535 - 1542
  • [3] Bachelder RE, 2001, CANCER RES, V61, P5736
  • [4] RNA interference: on the road to an alternate therapeutic strategy!
    Dave, RS
    Pomerantz, RJ
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2003, 13 (06) : 373 - 385
  • [5] STAT3 expression in salivary gland tumours
    de Araujo, Vera Cavalcanti
    Furuse, Cristiane
    Cury, Patricia Ramos
    Altemani, Albina
    de Araujo, Ney Soares
    [J]. ORAL ONCOLOGY, 2008, 44 (05) : 439 - 445
  • [6] Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C
    Dechow, TN
    Pedranzini, L
    Leitch, A
    Leslie, K
    Gerald, WL
    Linkov, I
    Bromberg, JF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) : 10602 - 10607
  • [7] Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
    Duan, Zhenfeng
    Foster, Rosemary
    Bell, Debra A.
    Mahoney, Jennifer
    Wolak, Kathryn
    Vaidya, Ami
    Hampel, Constanze
    Lee, Hang
    Seiden, Michael V.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5055 - 5063
  • [8] RNA interference: A practical approach
    Duxbury, MS
    Whang, EE
    [J]. JOURNAL OF SURGICAL RESEARCH, 2004, 117 (02) : 339 - 344
  • [9] Annual report to the Nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
    Edwards, BK
    Brown, ML
    Wingo, PA
    Howe, HL
    Ward, E
    Ries, LAG
    Schrag, D
    Jamison, PM
    Jemal, A
    Wu, XC
    Friedman, C
    Harlan, L
    Warren, J
    Anderson, RN
    Pickle, LW
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (19): : 1407 - 1427
  • [10] Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line
    Gariboldi, Marzia B.
    Ravizza, Raffaella
    Molteni, Roberta
    Osella, Domenico
    Gabano, Elisabetta
    Monti, Elena
    [J]. CANCER LETTERS, 2007, 258 (02) : 181 - 188